

Kristen E Labbe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/828627/publications.pdf>

Version: 2024-02-01

13
papers

527
citations

1163117

8
h-index

1372567

10
g-index

14
all docs

14
docs citations

14
times ranked

1060
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Clinical Characteristics and Outcomes of COVID-19â€“Infected Cancer Patients: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2021, 113, 371-380. | 6.3 | 153 |
| 2 | CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. <i>Cancer Cell</i> , 2020, 37, 37-54.e9. | 16.8 | 138 |
| 3 | <i>In Vivo</i> Epigenetic CRISPR Screen Identifies <i>Asf1a</i> as an Immunotherapeutic Target in <i>Kras</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2020, 10, 270-287. | 9.4 | 129 |
| 4 | Recent advances in preclinical models for lung squamous cell carcinoma. <i>Oncogene</i> , 2021, 40, 2817-2829. | 5.9 | 26 |
| 5 | Targeting the Atf7ipâ€“Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity. <i>Cancer Immunology Research</i> , 2021, 9, 1298-1315. | 3.4 | 18 |
| 6 | Epigenetic CRISPR Screens Identify <i>Npm1</i> as a Therapeutic Vulnerability in Nonâ€“Small Cell Lung Cancer. <i>Cancer Research</i> , 2020, 80, 3556-3567. | 0.9 | 17 |
| 7 | Loss of <i>TSC1/TSC2</i> sensitizes immune checkpoint blockade in nonâ€“small cell lung cancer. <i>Science Advances</i> , 2022, 8, eabi9533. | 10.3 | 16 |
| 8 | Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 85-94. | 2.5 | 15 |
| 9 | Investigation of a Mobile Health Texting Tool for Embedding Patient-Reported Data Into Diabetes Management (i-Matter): Development and Usability Study. <i>JMIR Formative Research</i> , 2020, 4, e18554. | 1.4 | 9 |
| 10 | DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome. <i>Clinical Cancer Research</i> , 2022, 28, 3824-3835. | 7.0 | 6 |
| 11 | Response to Cottu, Bozec, Basse, and Paoletti. <i>Journal of the National Cancer Institute</i> , 2021, 113, 344-345. | 6.3 | 0 |
| 12 | Response to Alpert and Taioli. <i>Journal of the National Cancer Institute</i> , 2021, 113, 503-504. | 6.3 | 0 |
| 13 | Response to Huang, Rivero-Hinojosa, Ma, et al. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1111-1112. | 6.3 | 0 |